Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Proceedings

Open Access

ATryn®: 1st GE (genetically engineered) animal success story for production of a human recombinant pharmaceutical

  • William Gavin1
BMC Proceedings20148(Suppl 4):O4

https://doi.org/10.1186/1753-6561-8-S4-O4

Published: 1 October 2014

The development of genetically modified (transgenic) animals for the production of human recombinant therapeutic proteins has been ongoing for more than 25+ years. Only recently in the last few years have products finally been approved that can now be found commercially on the market to the benefit of the medical community and patients that receive these lifesaving therapies. rEVO Biologics has a long history in transgenic technology for this purpose and has been recognized as the leader in this field. With the approval of ATryn® (antithrombin alpha) by both the EMA in 2007 and the FDA in 2009, rEVO Biologics set the standard and established significant milestones and "firsts" and is revolutionizing the application of this technology to recombinant therapeutic production. rEVO Biologics is now expanding upon this success by not only furthering the development of ATryn® into subsequent larger clinical indications but also by moving additional recombinant therapeutic proteins through the pipeline from development and into early and late stage clinical trials. The following presentation will highlight the company history and evolution for rEVO Biologics over the years and the developmental path for ATryn®. Specifically, areas to be reviewed will include the technology, the molecular biology involved, protein expression in the mammary gland, the purification scheme, antithrombin as a molecule and its clinical development, and the regulatory path for approval of ATryn® over the years. Additionally, the further clinical development of ATryn® into additional clinical indications and new proteins being taken through this development, clinical trial evaluation, and regulatory approval path will be discussed.

Authors’ Affiliations

(1)
rEVO Biologics

Copyright

© Gavin; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement